Pharmacokinetic consequences of pegylation

Drug Delivery

Volumn 13, Issue 6, 2006, Pages 399-409

  Hamidi, Mehrdad ^a   Azadi, Amir ^a   Rafiei, Pedram ^a  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

PEG; Pegylated Drugs; Pegylation; Pharmacokinetic; Systemic Drug Delivery

Indexed keywords

ACUMEN; ALPHA INTERFERON; ALPHA2A INTERFERON; ALPHA2B INTERFERON; ASPARAGINASE; ASPARAGINASE MACROGOL; BOVINE SERUM ALBUMIN; BRAIN DERIVED NEUROTROPHIC FACTOR; DOXORUBICIN; DRUG CARRIER; INTERLEUKIN 16; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 8 ANTIBODY; LACTOFERRIN; LIPOSOME; MACROGOL; MEGAKARYOCYTE GROWTH AND DEVELOPMENT FACTOR; METHOTREXATE; NANOPARTICLE; OLIGODEOXYNUCLEOTIDE; PACLITAXEL; PEGADEMASE; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PEGVISOMANT; POLYGLACTIN; POLYLACTIDE; PROTHECAN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; STREPTOKINASE; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACUTE LYMPHOCYTIC LEUKEMIA; CANCER COMBINATION CHEMOTHERAPY; CHEMISTRY; DRUG ABSORPTION; DRUG BINDING; DRUG CLEARANCE; DRUG COATING; DRUG CONJUGATION; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SOLUBILITY; ENZYME DEFICIENCY; HEPATITIS C; HUMAN; MOLECULAR DYNAMICS; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; TUMOR;

ANIMALS; CHEMISTRY, PHYSICAL; HUMANS; PEPTIDES; PHARMACEUTICAL PREPARATIONS; PHYSICOCHEMICAL PHENOMENA; POLYETHYLENE GLYCOLS; TISSUE DISTRIBUTION;

EID: 33749121585     PISSN: 10717544     EISSN: 15210464     Source Type: Journal    
DOI: 10.1080/10717540600814402     Document Type: Review

References (147)

1. Abuchowski, A., Kazo, G. M., Verhoest, C. R., et al. 1984. Cancer therapy with chemically modified enzymes. I. Antitumor properties of poly ethylene glycol-asparaginase. Cancer Biochem. Biophys. 7:175-186.
2. Aguayo, A., Cortes, J., Thomas, D., et al. 1999. Combination therapy with methotrexate, vincristin, polyethylene glycol conjugated-asparaginase, and prednisone in the treatment of patients with refractory or recurrent acute lymphoblastic leukemia. Cancer 86:1202-1209.
3. Alberts, D. S., and Garcia, D. J. 1997. Safety aspects of pegylated liposomal doxorubicin in patients with cancer. Drugs 54:30-35.
4. Algranati, N. E., Sy, S., and Modi, M. 1999. A branched methoxy 40 kDa poly ethylene glycol (PEG) moiety optimizes the pharmacokinetics (PK) of PEG-interferon α 2a (PEG-IFN) and may explain its enhanced efficacy in chronic hepatitis C (CHC). Hepatology 40 (suppl.):190A.
5. Allemann, E., Gravel, P., Leroux, J. C., et al. 1997. Kinetics of blood component adsorption on poly(D,L-lactic acid) nanoparticles: evidence of complement C3 component involvement. J. Biomed. Mater. Res. 37:229-234.
6. Bailon, P., Spence, C., Schaffer, C. A., et al. 1999. Pharmacological properties of five polyethylene glycol conjugates of interferon-α-2a. International Conference on Therapies for Viral Hepatitis, Dec. 6 1999, Maui, Hawaii.
7. Bailon, P., Palleroni, A., Schaffer, C. A., et al. 2001. Rationale design of a potent, long lasting form of interferon: A 40 kDa branched poly ethylene glycol-conjugated interferon α-2a for the treatment of hepatitis C. Bioconjug. Chem. 12:195-202
8. Bakker-Woudenberg, I. A. J. M., Kate, M. T. T., Guo, L., et al. 2002. Ciprofloxacin in polyethylene glycol-coated liposomes: efficacy in rat models of acute or chronic Pseudomonas aerations infection. Antimicrob. Agents Chemother. 46:2575-2581.
9. Bazile, D. V., Ropert, C., Huve, P. V., et al. 1992. Body distribution of fully biodegradable [14 C]-poly(lactic acid) nanoparticles coated with albumin after parenteral administration to rats. Biomaterials 13:1093-1102.
10. Bazile, D., Prud'homme, C., Bassoullet, M. T., et al. 1995. Stealth Me.PEG-PLA nanoparticles avoid uptake by the mononuclear phagocytes system. J. Pharm. Sci. 84:493-498.
11. Beauchamp, C. O., Gonias, S. L., Menapace, D. P., et al. 1983. A new procedure for the synthesis of polyethylene glycol-protein adducts; effects on function, receptor recognition, and clearance of superoxide dismutase, lactoferrin, and alfa 2-macroglobulin. Anal. Biochem. 131:25-33.
12. Bedeschi, A., Candiani, I., Geroni, C., and Capolongo, L. 1997. Water soluble camptothecin derivatives. Drugs Future 22:1259-1266.
13. Bonora, G. M., Ivanova, E., Zarytova, V., et al. 1997. Synthesis and characterization of high molecular mass polyethylene glycol-conjugated oligonucleotides. Bioconjugate Chem. 8:793-797.
14. th ed. Philadelphia: W.B. Saunders Company.
15. Brigger, I., Chaminade, P., Marsaud, V., et al. 2001. Tamoxifen encapsulation within polyethylene glycol-coated nanospheres. A new antiestrogen formulation Int. J. Pharm. 214:37-42.
16. Bucke, W. E., Leitzke, S., Diederichs, J. E., et al. 1998. Surface-modified amikacin liposomes: organ distribution and interaction with plasma proteins. J. Drug Target. 5:99-108.
17. Bukowski, R. M., Tendler, C., Cutler, D., et al. 2002. Treating cancer with PEG Intron: pharmacokinetic profile and dosing guidelines for an improved interferon-alpha-2b formulation. Cancer 95:389-396.
18. Bullock, J., Chowdhury, S., and Johnston, D. 1996. Characterization of poly (ethylene glycol) -modified super oxide dismutase: comparison of capillary electrophoresis and matrix assisted laser desorption /ionization mass spectroscopy. Anal. Chem. 68:3258-3264.
19. Burcovich, B., Verones, F. M., Zarytova, V., and Bonora, G. M. 1998. Branched polyethylene glycol(bPEG) conjugated antisense oligonucleotides. Nuleos. Nuleot. 17:1567-1570.
20. Burnham, N. L. 1994. Polymers for delivering peptides and proteins. Am. J. Hosp. Pharm. 51:210-218.
21. Calvo, P., Gouritin, B., Brigger, I., et al. 2001. PEGylated polycyanoacrylate nanoparticles as vector for drug delivery in prion diseases. J. Neuros. Methods 111:151-155.
22. Calvo, P., Gouritin, B., Chacun, H., et al. 2001. Long circulating PEGylated polycyanoacrylate nanoparticles as new drug carriers for brain delivery. Pharm. Res. 18:1157-1166.
23. Chandy, T., Rao, G. H., Wilson, R. F., and Das, G. S. 2002. Delivery of LMW heparin via surface coated chitosan/peg-alginate microspheres prevents thrombosis. Drug Deliv. 9:87-96.
24. Chatelut, E., Rostaing, L., Gregoire, N., et al. 1999. A pharmacokinetic model for alpha interferon administered subcutaneously. Br. J. Clin. Pharmacol. 47:365-371.
25. Cheng, T.-L., Chen, B.-M., Chern, J.-W., et al. 2000. Efficient clearance of poly(ethylene glycol)-modified immunoenzyme with anti-PEG monoclonal antibody for prodrug cancer therapy. Bioconjugate Chem. 11:258-266.
26. Chirila, T. V., Rakoczy, P. E., Garrett, K. L., et al. 2002. The use of synthetic polymers for delivery of therapeutic antisense oligodeoxynucleotides. Biomaterials 23:321-342.
27. Collen, D., Sinnaeve, P., Demarsin, E., et al. 2000. Polyethylene glycol-derivatized cysteine-substitution variants of recombinant staphylokinase for single bolus treatment of acute myocardial infarction. Cancer 102:1766-1772.
28. Conover, C. D., Greenwald, R. B., Pendri, A., et al. 1998. Camptothecin delivery systems: enhanced efficacy and tumor accumulation of camptothecin following its conjugation to polyethylene glycol via a glycine linker. Cancer Chemother. Pharmacol. 42:407-414.
29. Conover, C. D., Greenwald, R. B., Pendri, A., and Shum, K. L. 1999. Camptothecin delivery systems: the utility of amino acid spacers for the conjugation of camptothecin with polyethylene glycol to create prodrugs. Anti-Cancer Drug Design 14:499-506.
30. Conover, C. D., Pendri, A., Lee, C., et al. 1997. Camptothecin delivery systems: the antitumor activity of a camptothecin 20-O-polyethylene glycol ester transport form. Anti Cancer Res. 17:3361-3368.
31. Couvreur, P., and Aubry, J. 1983. Monoclonal antibodies for the targeting of drugs: application to nanoparticles. In Topics in Pharmaceutical Sciences, eds. Breimer, D.D., and Speises, P., p 305-316. Amsterdam: Elsevier Sciences Publishers B.V.
32. Davis, F. F., Abuchowski, A., Van Es T., et al. 1978. Enzyme-polyethylene glycol adducts: modified enzymes with unique properties. Enzyme Eng. 4:169-173.
33. Diwan, M., and Park, T. G. 2001. Pegylation enhances protein stability during encapsulation in PLGA microspheres. J. Control. Rel. 73:233-244.
34. Dosio, F., Arpicco, S., Brusa, P., et al. 2001. Poly(ethylene glycol)-human serum albumin-paclitaxel conjugates: preparation, characterization, and pharmacokinetics. J. Control. Rel. 46:107-117.
35. Edwards, C. K. 1999. Pegylated recombinant human soluble tumor necrosis factor receptor type (rHu-STNF-RI): a novel high affinity TNF receptor designed for chronic inflammatory disease. Ann. Rheum. Dis. 58:I73-I81.
36. Eliason, J. F. 2001. Pegylated cytokines-potential application in immunotherapy of cancer.Biodrugs 15:705-711.
37. Esslinger, H. V., Haas, S., Maurer, R., et al. 1997. Pharmacodynamic and safety results of PEG-Hirudin in healthy volunteers. Thromb. Haemost. 77:911-919.
38. F. Hoffmann-La Roche, Ltd., data on file.
39. Francis, G. E., Fisher, D., Delgado, C., et al. 1998. PEGylation of cytokines and other therapeutic proteins and peptides: the importance of biological optimization of coupling techniques. Int. J. Hematol. 68:1-18.
40. Fresta, M., Fontana, G., Bucolo, C., et al. 2001. Ocular tolerability and in vivo bioavailability of poly(ethylene glycol) (PEG)-coated polyethyl-2-cyanoacrylate nanosphere-encapsulated acyclovir. J. Pharm. Sci., 90:288-297.
41. Fujita, T., Nishikawa, M., Ohtsubo, Y., et al. 1994. Control of in vivo fate of albumin derivatives utilizing combined chemical modification. J. Drug Target. 2:157-165.
42. Gabizon, A., Chemla, M., Tzemach, D., et al. 1996. Liposome longevity and stability in circulation: effects on the in vivo delivery to tumors and therapeutic efficacy of encapsulated anthracyclines J. Drug Target. 3:391-398.
43. Gabizon, A., and Martin, F. 1997. Polyethylene glycol-coated liposomal doxorubicin: rationale for use in solid tumors. Drugs 54:15-21.
44. Garman, J., and Kalindjian, S. B. 1987. The preparation and properties of novel reversible polymer-protein conjugates. 2-methoxy polyethylene (5000) glycoxymethylene-3-methylmaleyl conjugates of plasminogen activators. FEBS Lett. 223-361.
45. Gbadamosi, J. K., Hunter, A. C., and Moghimi, S. M. 2002. PEGylation of microspheres generates a heterogeneous population of particles with differential surface characteristics and biological performance. FEBS Lett 532:338-344.
46. Chognot, D., Six, J. L., Leonard, M., et al. 2003. Physicochemical evaluation of PLA nanoparticles stabilized by water-soluble MPEO-PLA block copolymers. J. Colloid Interface Sci. 268:441-447.
47. Glue, P., Fang, J., Sabo, R., et al. 1999a. A dose ranging study of PEG-Intron and ribavirin in chronic hepatitis C-safety, efficacy, and virological rational. Hepatology 30:303A.
48. Glue, P., Rouzier-panis, R., Raffanel, C., et al. 1999b. PEG-interferon-α 2b: pharmacokinetics, pharmacodynamics, safety and preliminary efficacy data. Hepatology 30:189AA.
49. Grace, M., Youngster, S., Gitlin, G., et al. 2001. Structural and biologic characterization of pegylated recombinant IFN-α-2b. J. IFN Cytokine Res. 21:1103-1115.
50. Greenwald, R. B., Pendri, A., and Bolikal, D. 1995. Highly water soluble taxol derivatives. 7-polyethylene glycol carbamates and carbonates. J. Org. Chem. 60:331-336.
51. Greenwald, R. B., Gilbert, C. W., Pendri, A., et al. 1996a. Drug delivery systems: water soluble taxol 2-poly (ethylene glycol) ester prodrugs-design and in vivo effectiveness. J. Med. Chem. 39:424-431.
52. Greenwald, R. B., Pendri, A., Conover, C., et al. 1996b. Drug delivery systems: 2. Camptothecin 20-O-poly(ethylene glycol) ester transport forms. J. Med. Chem. 39:1938-1940.
53. Greenwald, R. B., Pendri, A., Conover, C. V., et al. 1998. Camptothecin-20-PEG ester transport forms: the effect of space groups on antitumor activity. Bioorg. Med. Chem. 6:551-562.
54. Greenwald, R. B., Conover, C. V., Pendri, A., et al. 1999. Drug delivery of anticancer agents: water soluble 4-poly(ethylene glycol) derivatives of the lignan, podophylotoxin. J. Control. Rel. 61:281-294.
55. Gref, R., Minamitake, Y., Peracchia, M. T., et al. 1994. Biodegradable long-circulating polymeric nanospheres. Science 263:1600-1603.
56. Gref, R., Domb, A., Quellec, P., et al. 1995. The controlled intravenous delivery of drugs using PEG-coated sterically stabilized nanospheres. Adv. Drug. Deliv. Rev. 16:215-233.
57. Gref, R., Lück, M., Quellec, P., et al. 2000. 'Stealth' corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption. Colloids Surfaces B: Biointerfaces 18:301-313.
58. Gupta, S. K., Pittance, A. L., Swan, S. K., et al. 2002. Single dose pharmacokinetics and safety of pegylated interferon alfa-2b in patients with chronic renal dysfunction.J. Clin. Pharamacol. 42:1109-1115.
59. Harris, J. M., Martin, N. E., and Modi, M. 2001. Pegylation: a novel process for modifying pharmacokinetics. Clin. Pharmacokinet. 40:539-551.
60. Harris, J. M., Zalipsky, S., (eds.). 1997. Poly(ethylene glycol): Chemistry, and Biomedical Applications. Washington, DC: ACS Books.
61. He, X. H., Shaw, P. C., and Tam, S. C. 1995. Reducing the immunogenicity and improving the in vivo activity of trichosantin by site directed pegylation. Life Sci. 65:355-368.
62. Heathcof, E. J., Shiffman, M. L., Cooksley, G., et al. 1999. Multinational evaluation of the efficacy and safety of once weekly PEG-interferon α-2a (PEG-IFN) in patients with chronic hepatitis C (CHC) with compensation cirrhosis. Hepatology 30(suppl.):316A.
63. Hershfield, M. S. 1995. PEG-ADA replacement therapy for adenosine deaminase deficiency: an update after 8.5 years. Clin. Immunol. Immunopathol. 76:S228-S232.
64. Hershfield, M. S. 1997. Biochemistry and poly (ethylene glycol)-modified adenosine deaminase (PEG-ADA). In Poly (ethylene glycol): Chemistry and Biological Applications, eds. Harris, J.M., and Zolipsky, S., 134-144. Washington, DC: ACS Books.
65. Hershfield, M. S., Chaffee, S., Koro-jonson, L., et al. 1991. Use of site directed mutagenesis to enhance the epitope shielding effect of covalent modification of protein with poly ethylene glycol. Proc. Natl. Acad. Sci. USA 88:7185-7189.
66. Hokom, M. M., Lacey, D., Kinsler, O., et al. 1995. Megakaryocyte growth and development factor abrogates the lethal thrombocytopenia associated with carboplatin and irradiation in mice. Blood 86:4486-4892.
67. Holle, L. M. 1997. Pegaspargase: alternative? Ann. Pharmacother. 31:616-624, 655-656.
68. Holmes, F. A., O'Shaughnessy, J. A., Vukelja, S., et al. 2002. Blinded, randomized, multicentre study to evaluate single administration PEG filgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J. Clin. Oncol. 20:727-731.
69. Hurwitz, E., Klapper, L. N., Wilchek, M. Y., et al. 2000. Inhibition of tumor growth by poly(ethylene glycol) derivatives of anti-ErbB2 antibodies. Cancer Immunol. Immunother. 49:226-234.
70. Illum, L., Jones, P. D. E., Kreuter, J., et al. 1983. Adsorption of monoclonal antibodies to polyhexylcyanoacrylate nanoparticles and subsequent immunospecific binding to tumour cells in vitro. Int. J. Pharm. 17:65-76.
71. Illum, L., Jones, P. D., Baldwin, R. W., and Davis S. S. 1984. Tissue distribution of poly(hexyl 2-cyanoacrylate) nanoparticles coated with monoclonal antibodies in mice bearing human tumor xenografts. J. Pharmacol. Exp. Ther. 230:733-736.
72. Illum, L., Church, A. E., Butterworth, M. D., et al. 2001. Development of systems for targeting the regional lymph nodes for diagnostic imaging. Pharm Res. 18:640-645.
73. Imaz, I. A. 2002. New formulation of interferon in treatment of hepatitis: peginterferon alfa-2b (pegintron). Farm. Hosp. Spain 133:9-10, 12-15, CP1.
74. Ishida, O., Maruyama, K., Tanahashi, H., et al. 2001. Liposomes bearing polyethyleneglycol-coupled transferrin with intracellular targeting property to the solid tumors. Pharm. Res. 18:1042-1048.
75. Iwanaga, K., Ono, S., Narioka, K., et al. 1997. Oral delivery of insulin by using surface coating liposomes: improvement of stability of insulin in GI tract. Int. J. Pharm. 157:73-80.
76. Jaschke, A., Furste, J. P., Nordhoff, E., et al. 1994. Synthesis and properties of oligodeoxyribonucleotide-polyethylene glycol conjugates. Nuleic Acids Res. 22:4810-4817.
77. Jaschke, A., Furste, J. P., Cech, D., and Erdmann, V. A. 1993. Automated incorporation of polyethylene glycol into synthetic oligonuleotides. Tetrahedron Lett. 34:301-304.
78. Katre, N. V. 1993. The conjugation of proteins with polyethylene glycol and other polymers: altering properties of proteins to enhancing their therapeutic potential. Adv. Drug Del. Rev. 10:91-114.
79. Kawaguchi, T., Asakawa, H., Tashiro, T., et al. 1995. Atachability, binding activity, and plasma concentration in mice of an oligodeoxynucleotide modified at 5′-terminal with poly(ethylene glycol). Biol. Pharm. Bull. 18:474-576.
80. Kim, T. H., Lee, H. and Park, T. G. 2002. Pegylated recombinant human epidermal growth factor (rhEGF) for sustained release from biodegradable PLGA microspheres. Biomaterials 23:2311-2317.
81. Kinstler, O. B., Brems, D. N., Lauren, S. L., et al. 1996. Characterization and stability of N- terminally PEGylated rhG-CSF. Pharm. Res. 13:996-1002.
82. Knauf, M. J., Bell, D. P., Hirtzer, P., et al. 1988. Relationship of effective molecular size to systemic clearance in rats of recombinant interleukin-2 chemically modified with water-soluble polymers. J. Biol. Chem. 263:15064-15070.
83. 2 by amine specific PEGylation with preserved bioactivity. Int. J. Pharm. 198:83-95.
84. Kozlowski, A., and Harris, J. M. 2001. Improvements in protein PEGylation: pegylated interferons for treatment of hepatitis C. J. Control. Rel. 72:217-224.
85. Kubiak, C., Manil, L., and Couvreur, P. 1988. Sorptive properties of antibodies onto cyanoacrylic nanoparticles. Int J Pharm 41:181-187.
86. Laverman, P., Dams, E. Th. M., Storm, G., et al. 2001. Microscopic localization of PEG-liposomes in a rat model of focal infection. J. Control. Rel. 75:347-355.
87. Lee, K. C., Tak, K. K., Park, M. O., et al. 1999. Preparation and characterization of polyethylene-glycol-modified salmon calcitonins. Pharm. Dev. Tech. 4:269-275.
88. Lee, L. S., Conover, C., Shi, C., et al. 1999. Prolonged circulating lives of single-chain Fv proteins conjugated with polyethylene glycol: a comparison of conjugation chemistries and compounds. Bioconjug. Chem. 10:973-981.
89. Levchenko, T. S., Rammohan, R., Lukyanov, A. N., et al. 2002. Liposome clearance in mice: the effect of a separate and combined presence of surface charge and polymer coating. Int. J. Pharm. 240:95-102.
90. Li, S., Yang, Z., Sun, X., et al. 2004. Protein carboxyl amidation increases the potential extent of protein poly ethylene glycol conjugation. Anal. Biochem. 330:204-271.
91. Li, Y., Pei, Y., Zhang, X., et al. 2001. PEGylated PLGA nanoparticles as protein carriers: synthesis, preparation and biodistribution in rats. J. Control. Rel. 71:203-211.
92. Lusting, R., Byhardt, R., Diab, S., et al. 1999. A clinical phase IB study of PEG-hemoglobin in patients receiving palliative fractioned radiation for solid tumors. J. Clin. Oncol. 17:1750.
93. Manil, L., Roblot-Treupel, L., and Couvreur P. 1986. Isobutyl cyanoacrylate nanoparticles as a solid phase for an efficient immunoradiometric assay. Biomaterials 7:212-216.
94. Martinez, A., Pendri, A., and Greenwald, R. B. 1997. Branched poly(ethylene glycol) linkers. Macromol. Chem. Phys. 198:2489-2498.
95. Maruyama, K., Ishida, O., Takizawa, T., and Moribe, K. 1999. Possibility of active targeting to tumor tissues with liposomes. Adv. Drug Deliv. Rev. 40:89-102
96. Medina, J., Garcia Buey, L., Moreno Monteagudo, J. A., et al. 2003. Therapeutic advantages of pegylation of interferon alpha in chronic hepatitis C. Rev. Esp. Enferm. Dig. 95:561-574.
97. Moghimi, S. M., Hunter, A. C., and Murray, J. C. 2001. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol. Rev. 53:283-318.
98. Moghimi, S. M. 2002. Chemical camouflage of nanospheres with a poorly reactive surface: towards development of stealth and target-specific nanocarriers. Biochim. Biophys. Acta. 1590:131-139.
99. Molineux, G. 2003. Pegfilgrastim: using pegylation technology to improve neutropenia support in cancer patients. Anticancer Drugs 14:259-264.
100. Monfardini, C., Schiavon, O., Caliceti, P., et al. 1995. A branched monomethoxypoly (ethylene glycol) for protein modification. Bioconjug. Chem. 6:62-69.
101. Morstyn, G., Foote, M., Walker, T., and Molineux, G. 2001. Filgrastim(rmetHuG-CSF) in the 21st century: SD/01. Acta Haematol. 105:151-155.
102. Mosqueira, V. C., Legrand, P., Gulik, A., et al. 2001. Relationship between complement activation, cellular uptake and surface physicochemical aspects of novel PEG-modified nanocapsules. Biomaterials 22:2967-2979.
103. Murakami, Y., Tabata, Y., and Ikada, Y. 1997. Tumor accumulation of poly(ethylene glycol) with different with molecular weights after i.v. injection. Drug Del. 4:23-32.
104. Nieforth, K.A,, Nadeau, R., Patel, I.H., et al. 1996. Use of an indirect pharmacodynamic stimulation model of MX protein induction to compare in vivo activity of interferon alfa-2a and a polyethylene glycol-modified derivative in healthy subjects. Clin. Pharmacol. Ther. 59:636-646.
105. Noguchi, Y., Wan, J., Duncan, R., et al. 1998. Early phase tumor accumulation of macromolecules: a great difference in clearance rate between tumor and normal tissues. Jap. J. Cancer 89:397-416.
106. 125 I-PLA-b-PEO block copolymers in rats. Pharm. Dev. Technol. 8:153-161.
107. Nucci, M. L., Shorr, R. G., and Abuchowski, A. 1996. PEG-Hemoglobin.Drug. Future 21:29-32.
108. O'Brien, C., Pockros, P., Reddy, R., et al. 1999. A double-blind, multicentre, randomized, parallel dose-comparison study of six regimens of 5KDa, linear peginterferon α-2a compared with roferon-ain patients with chronic hepatitis C. International Conference on Therapies for Viral Hepatitis December 6, 1999, Maui, Hawaii.
109. Ochoa, L., Tolcher, A. W., Rizzo, J., et al. 2000. A phase I study of PEG-camptothecin(PEG-CPT) in patients with advanced solid tumors: a novel formulation for an insoluble but active agent. J. Clin. Oncol. 19:198a.
110. Otsuka, H., Nagasaki, Y., and Kataoka, K. 2003. PEGylated nanoparticles for biological and pharmaceutical applications. Adv. Drug Deliv. Rev. 55:403-419.
111. Pardridge, W. M., Wu, D., and Sakane, T. 1998. Combined use of carboxyldirected protein pegylation and vector-mediated blood-brain barrier drug delivery system optimized brain uptake of brain derived neurotrophic factor following intravenous administration. Pharm. Res. 15:576-582.
112. Pedder, S. C. 2003. Pegylation of interferon alfa: structural and pharmacokinetic properties. Semin Liver Dis. 23suppl. 1:19-22.
113. Pendri, C., Conover, C. D., and Greenwald, R. B. 1998. Antitumor activity of paclitaxel -2′-glycinate conjugated to poly(ethylene glycol): a water-soluble prodrug. Anti-Cancer Drug Design 13:387-395.
114. Peracchia, M. T., Fattal, E., Desmaele, D., et al. 1999. Stealth PEGylated polycyanoacrylate nanoparticles for intravenous administration and splenic targeting. J.Control. Rel. 60:121-128.
115. Rajagopalan, S., Gonias, S. L., and Pizzo, S. V. 1985. A nonantigenic covalent streptokinase-polyethylene glycol complex with plasminogen activator function. J. Clin. Invest. 75:413-419.
116. Reddy, K. R. 2000. Controlled-release, pegylation, liposomal formulations: new mechanisms in the delivery of injectable drugs. Ann. Pharmacother. 34:915-923.
117. Riley, T., Govender, T., Stolnik, S., et al. 1999. Colloidal stability and drug incorporation aspects of micellar-like PLA-PEG nanoparticles. Colloids Surfaces B: Biointerfaces 16:147-159.
118. Roberts, M. J., Bentley, M. D., and Harris, J. M. 2002. Chemistry for peptide and protein PEGylation. Adv. Drug Del. Rev. 54:459-476.
119. Sahli, H., Tapon-Bretaudiere, J., Fischer, A. M., et al. 1997. Interactions of poly(lactic acid) and poly(lactic acid-co-ethylene oxide) nanoparticles with the plasma factors of the coagulation system. Biomaterials 18:281-288.
120. Seelig, B., and Jasche, A. 1997. Site specific modification of enzymatically synthesized RNA: transcription initiation and Diels Alder reaction. Tetrahedran Lett. 38:7729-7732.
121. Sharp, M., Easthope, S. E., Keating, G. M., and Lamb, H. M. 2002. Polyethylene glycol-liposomal doxorubicin. Drugs 62:2089-2126.
122. Shiffman, M., Pockros, P. J., Reddy, R. K., et al. 1999. A controlled, randomized, multicentre, ascending dose phase II trial of pegylated interferon α-2a(PEG) vs. standard interferon α-2a(IFNα) for treatment of chronic hepatitis C. Gastroenterology 116:1275.
123. Somack, R., Saifer, M. G., and Williams, L. D. 1991. Preparation of long-acting superoxide dismutase using high molecular weight polyethylene glycol(41,000-72,000 daltons). Free Radic. Res. Commun. 12-13:553-562.
124. Stolnik, S., Dunn, S. E., Garnett, M. C., et al. 1994. Surface modification of poly(lactide-co-glycolide) nanospheres by biodegradable poly(lactide)-poly(ethylene glycol) copolymers. Pharm. Res. 11:1800-1808.
125. Sulkowski, M., Reindollar, R., and Yu, J. 1999. Combination therapy with peginterferon α-2a(PEG-IFN) and ribavirin in the treatment of patients with chronic hepatitis C(CHC): a phase II open-label study. Hepatology 30:197A.
126. Sun, X., Yang, Z., Li, S., et al. 2003. In vitro efficacy of recombinant methioninase is enhanced by the combination of polyethylene glycol and pyridoxal 5′ phosphate supplementation. Cancer Res. 63:8377-8383.
127. Trainer, P. J., et al. 2000. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N. Engl. J. Med. 342:1171-1177.
128. Tsutsumi, Y., Kihira, T., Tsunoda, S., et al. 1995. Molecular design of hybrid tumour necrosis factor alfa with polyethylene glycol increases its anti-tumour potency. Br. J. Cancer 71:963-968.
129. Tsutsumi, Y., Tsunoda, S., Kamada, H., et al. 1997. PEGylation of interleukin-6 effectively increases its thrombopoietic potency. Thromb. Haemost. 77:168-173.
130. Verrecchia, T., Spenlehauer, G., Bazile, D. V., et al. 1995. Non-stealth (poly(lactic acid/albumin)) and stealth (poly(lactic acid-polyethylene glycol)) nanoparticles as injectable drug carriers. J. Control. Rel. 36:49-61.
131. Vorobjev, P. E., Zarytova, V. F., and Bonora, G. M. 1999. Oligonucleotide conjugated to linear and branched high molecular weight polyethylene glycol as substrates for RNAse H. Nucleos. Nucleot. 18:2745-2750.
132. Wang, Y., Youngster, S. Bausch, J., et al. 2000. Identification of major positional isomers of pegylated IFNalfa-2b. Biochemistry 39:10634-10040.
133. Wills, R. J., Dennis, S., Speigel, H. E., et al. 1984. Interferon kinetics and adverse reactions after intravenous, intramuscular, and subcutaneous injection. Clin. Pharmacol. Ther. 35:722-727.
134. Woghiren, C., Sharma, B., and Stein, S. 1993. Protected thiol-polyethylene glycol: a new activated polymer for reversible protein modification. Bioconjug. Chem. 3:314.
135. Xu, Z-X., Patel, I., and Joubert, P. 1998. Single-dose safety/tolerability and pharmacokinetic/pharmacodynamics (PK/PD) following administration of ascending subcutaneous doses of pegylated interferon (PEG-IFN) and interferon α-2a (IFN α-2a) to healthy subjects [abstract]. Hepatology 28 Suppl.: 702.
136. Yamaoka, T., Tabata, Y., and Ikada, Y. 1994. Distribution and tissue uptake of poly(ethylene glycol) with different molecular weights after intravenous administration to mice. J. Pharm. Sci. 83:601-606.
137. Yang, J. C., Topalian, S. L. Schwartzentruber, D. J., et al. 1995. The use of polyethylene glycol modified interleukin-2(PEG-IL-2) in the treatment of patients with metastatic renal cell carcinoma and melanoma. A phase I study and randomized prospective study comparing IL-2 alone versus IL-2 combined with PEG-IL-2.Cancer 76:687-694.
138. Yoo, S. D., Jun, H., Shin, B. S., et al. 2000. Pharmacokinetic deposition of polyethylene glycol modified salmon calcitonins in rats. Chem. Pharm. Bull. 48:1921-1924.
139. Yuan, F., Leuning, M., Huang, S. K., et al. 1994 . Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. Cancer Res. 54:3352-3356.
140. Zalipsky, S. 1995. Chemistry of polyethylene glycol conjugates with biologically active molecules. Adv. Drug Deliv. Rev. 16:157-182.
141. Zalipsky, S., Gilon, C., and Zilkha, A. 1985. Attachment of drugs to polyethylene glycols. Eur. Polym. J. 19:1177-1183.
142. Zalipsky, S., and Lee, C. 1992. Use of functionalized poly(ethylene glycol)s for modification of polypeptides, In Poly(ethylene glycol) Chemistry: Biotechnical and Biomedical Applications ed. Harris, J. M., 347-370. New York: Plenum Press.
143. Zambaux, M. F., Faivre-Fiorina, B., Bonneau, F., et al. 2000. Involvement of neutrophilic granulocytes in the uptake of biodegradable non-stealth and stealth nanoparticles in guinea pig. Biomaterials 21:975-980.
144. Zeuzem, S., Feinman, S.V., Rasenack, J., et al. 2000. Evaluation of the safety and efficacy of once-weekly peginterfron α-2a (PEGASYS™) for chronic hepatitis C: a multinational randomized study. The European Association for the Study of the Liver, May 1-4, 2000. Rotterdam, the Netherlands.
145. Zeuzem, S., Heathcote, J. E., Martin, N., et al. 2001. PegIFN alfa-2a(40 kDa) monotherapy: a novel agent for chronic hepatitis C therapy. Expert Opin. Investig. Drugs 10:2201-2213.
146. Zhao, H., Lee, C., Sai, P., et al., 2000. 20-O-acylcamptothecin derivatives: evidence for lacton stabilization. J. Org. Chem. 65:4601-4606.
147. Zhao, X., and Harris, J. M. 1997. Novel degradable poly(ethylene glycol) esters for drug delivery, In Poly (ethylene glycol): Chemistry and Biological Applications eds. Harris, J. M., and Zolipsky, S., 458-482. Washington, DC: ACS Books.